Wall Street Zen Downgrades WAVE Life Sciences (NASDAQ:WVE) to Strong Sell

WAVE Life Sciences (NASDAQ:WVE) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “strong sell” rating in a report released on Saturday.

WVE has been the subject of a number of other reports. Truist Financial started coverage on shares of WAVE Life Sciences in a research note on Wednesday, April 29th. They issued a “buy” rating and a $15.00 price target for the company. Wells Fargo & Company increased their price objective on shares of WAVE Life Sciences from $13.00 to $14.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Canaccord Genuity Group dropped their target price on shares of WAVE Life Sciences from $52.00 to $43.00 and set a “buy” rating on the stock in a report on Thursday, April 30th. Wedbush cut their target price on shares of WAVE Life Sciences from $15.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday. Finally, HC Wainwright reiterated a “buy” rating on shares of WAVE Life Sciences in a research note on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.88.

WAVE Life Sciences Price Performance

WAVE Life Sciences stock opened at $5.51 on Friday. WAVE Life Sciences has a one year low of $5.02 and a one year high of $21.73. The business’s fifty day moving average is $5.98 and its 200 day moving average is $8.94. The stock has a market capitalization of $1.09 billion, a PE ratio of -5.06 and a beta of -1.26.

WAVE Life Sciences (NASDAQ:WVE) last issued its earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). The business had revenue of $2.27 million during the quarter, compared to analysts’ expectations of $7.45 million. WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%. As a group, sell-side analysts expect that WAVE Life Sciences will post -1.12 EPS for the current fiscal year.

Institutional Trading of WAVE Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CWM LLC boosted its stake in shares of WAVE Life Sciences by 6,729.0% during the 4th quarter. CWM LLC now owns 2,117 shares of the company’s stock worth $36,000 after acquiring an additional 2,086 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in WAVE Life Sciences by 645.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock worth $38,000 after purchasing an additional 1,942 shares during the period. Russell Investments Group Ltd. lifted its position in WAVE Life Sciences by 1,441.6% during the third quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock valued at $73,000 after purchasing an additional 9,284 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in WAVE Life Sciences by 44.8% during the second quarter. Tower Research Capital LLC TRC now owns 11,658 shares of the company’s stock valued at $76,000 after purchasing an additional 3,609 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new position in WAVE Life Sciences during the second quarter valued at $80,000. 89.73% of the stock is owned by hedge funds and other institutional investors.

Key WAVE Life Sciences News

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE said dosing is underway in the Phase 2a multidose portion of its INLIGHT trial evaluating WVE-007, an INHBE GalNAc-siRNA treatment, in people with obesity and related conditions. The study could also support future development in MASH, type 2 diabetes and other cardiometabolic diseases. WAVE Life Sciences Second-Quarter Results and Business Update
• Positive Sentiment: Citigroup maintained a Buy rating despite lowering its price target from $24 to $19, implying significant potential upside from the current trading level. Benzinga analyst update
• Positive Sentiment: Wedbush also retained an Outperform rating while reducing its target from $15 to $12, indicating analysts remain constructive on WVE’s pipeline despite lower near-term valuation expectations. The Fly analyst update
• Negative Sentiment: Second-quarter adjusted loss was $0.34 per share, worse than the $0.31 consensus estimate and the $0.31 loss reported a year earlier. WAVE Life Sciences Q2 Earnings Report
• Negative Sentiment: Revenue of $2.27 million substantially missed analysts’ $6.53 million expectation, reinforcing concerns about the company’s limited current commercial revenue and ongoing losses. WAVE Life Sciences Earnings Report
• Negative Sentiment: The reductions in both analyst price targets suggest expectations for WVE’s near-term valuation have moderated, even though the firms kept bullish ratings.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.